-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The proportion of patients with locally advanced lung cancer (stage III) that can be treated surgically is low.
The response rate of PD-1 inhibitor monotherapy is only about 20%.
How to improve the response rate? In 2021, the American Society of Clinical Oncology ASCO reported a study that combined with PD-1 inhibitor pembrolizumab (Drug K) after concurrent radiotherapy and chemotherapy for stage III lung cancer can achieve a treatment response rate of 70%.
The cancer degree will be shared with everyone for the first time.
KEYNOTE-799: The design of clinical trials of K drugs and concurrent radiotherapy and chemotherapy for the treatment of lung cancer is a very important subject.
Different drugs and treatment combinations must be just right.
If the dosage is not enough, sufficient curative effect cannot be achieved; if the drug is overdose, serious adverse reactions will occur.
What is the beauty of the design of the clinical trial of KEYNOTE-799? Let's take a look together.
This clinical trial enrolled patients with non-resectable stage III non-small cell lung cancer.
The study was divided into two groups: A group of 112 patients, including squamous and non-squamous non-small cell lung cancer, used chemotherapy regimens It is carboplatin combined with paclitaxel.
· A total of 73 patients in group B included only non-squamous non-small cell lung cancer.
The chemotherapy regimen used was pemetrexed combined with cisplatin.
Figure 1.
KEYNOTE-799-clinical trial design diagram.
The dosages of the two groups throughout the treatment cycle are shown in Figure 1: Group A patients: first used a cycle of chemotherapy combined with PD-1 inhibitor K drugs, in the second and third cycles Reduce the chemotherapy dose and start adding radiotherapy.
After that, K drug has been used for maintenance treatment for 14 cycles.
Group B patients: Pemetrexed combined with cisplatin was used in the first three cycles, and radiotherapy was added to the second and third cycles, but the chemotherapy drug dose was not reduced.
After three cycles, K medicine has been used for maintenance treatment.
This is a relatively comprehensive clinical trial design, with anti-PD-1 treatment as the main line.
Chemotherapy used three cycles, while radiotherapy only used two cycles.
Chemotherapy and radiotherapy played an appropriate role in assisting in the treatment, and avoided The patient is intolerant or has serious adverse reactions.
70% treatment response rate, negative PD-L1 expression can also benefit.
The clinical trial results show that the treatment response rates of the AB groups are 70.
5% and 70.
6%, respectively, reaching the targeted drug treatment response rate.
Figure 2.
The treatment response rate of concurrent radiotherapy and chemotherapy combined with PD-1 in the treatment of stage III lung cancer.
As shown in the figure above, patients in group A and B have achieved very high treatment response rates, and can be obtained regardless of whether PD-L1 expression is negative or positive.
Benefit, that is to say, with such a treatment plan, there is no need to do additional PD-L1 expression detection.
· Patients in group A: The response rate for treatment with PD-L1 expression <1% was 66.
7%, and the response rate for treatment with PD-L1 expression ≥ 1% was 75.
8%.
· Group B patients: The response rate to treatment with PD-L1 expression <1% was 71.
4%, and the response rate to treatment with PD-L1 expression ≥ 1% was 72.
5%.
The treatment response rate of squamous cell carcinoma in group A was 71.
2%, and the treatment response rate of non-squamous cell carcinoma was 69.
2%, which means that the treatment response rates of different subtypes of lung cancer are very similar.
Adverse reactions: 9 patients in group A developed pneumonia of grade 3 or higher, with a probability of 8%.
Seven patients in group B developed pneumonia of grade 3 or higher.
The probability of any adverse reaction above grade 3-5 in group A and group B was 64.
3% and 50%, respectively.
The overall security is controllable.
Implications This clinical trial enrolled patients with locally advanced (stage III) lung cancer, but its findings have implications for many patients with advanced lung cancer or other solid tumors.
At present, the response rate of PD-1 inhibitors in single-agent treatment of lung cancer is only about 20%.
Combining chemotherapy and radiotherapy to assist immunotherapy can improve the efficiency of treatment, but combined treatment will increase the probability of adverse reactions.
So, which drugs are combined? What dose is it administered? How long is the period of use for each drug? These problems need to be verified in clinical trials, and only treatments with controllable risks and superior curative effects will eventually be used in the clinic.
From the data of the KEYNOTE-799 trial, we can see that by optimizing the course of radiotherapy and appropriately reducing the dose of chemotherapeutic drugs by performing radiotherapy and chemotherapy while using drug K, the treatment efficiency can be improved, and the adverse reactions can be controlled.
Looking forward to more clinical trials in the future to bring us more and better treatment options.
Download the Cancer Degree APP to learn more about immunotherapy.
Reference: https://meetinglibrary.
asco.
org/record/196541/abstract Click below to learn more about clinical trial projects.
Children are the flowers of the motherland.
On Children’s Day, a festival that symbolizes hope, cancer degrees will work with you.
Overcome the disease.
Participate in the following interactions to learn more about the functions of the APP.
If it is helpful, you are welcome to download and use the Cancer App.
Click me, click me, click me, click me, click me, click me, review past issues, slide to read more past issues
The response rate of PD-1 inhibitor monotherapy is only about 20%.
How to improve the response rate? In 2021, the American Society of Clinical Oncology ASCO reported a study that combined with PD-1 inhibitor pembrolizumab (Drug K) after concurrent radiotherapy and chemotherapy for stage III lung cancer can achieve a treatment response rate of 70%.
The cancer degree will be shared with everyone for the first time.
KEYNOTE-799: The design of clinical trials of K drugs and concurrent radiotherapy and chemotherapy for the treatment of lung cancer is a very important subject.
Different drugs and treatment combinations must be just right.
If the dosage is not enough, sufficient curative effect cannot be achieved; if the drug is overdose, serious adverse reactions will occur.
What is the beauty of the design of the clinical trial of KEYNOTE-799? Let's take a look together.
This clinical trial enrolled patients with non-resectable stage III non-small cell lung cancer.
The study was divided into two groups: A group of 112 patients, including squamous and non-squamous non-small cell lung cancer, used chemotherapy regimens It is carboplatin combined with paclitaxel.
· A total of 73 patients in group B included only non-squamous non-small cell lung cancer.
The chemotherapy regimen used was pemetrexed combined with cisplatin.
Figure 1.
KEYNOTE-799-clinical trial design diagram.
The dosages of the two groups throughout the treatment cycle are shown in Figure 1: Group A patients: first used a cycle of chemotherapy combined with PD-1 inhibitor K drugs, in the second and third cycles Reduce the chemotherapy dose and start adding radiotherapy.
After that, K drug has been used for maintenance treatment for 14 cycles.
Group B patients: Pemetrexed combined with cisplatin was used in the first three cycles, and radiotherapy was added to the second and third cycles, but the chemotherapy drug dose was not reduced.
After three cycles, K medicine has been used for maintenance treatment.
This is a relatively comprehensive clinical trial design, with anti-PD-1 treatment as the main line.
Chemotherapy used three cycles, while radiotherapy only used two cycles.
Chemotherapy and radiotherapy played an appropriate role in assisting in the treatment, and avoided The patient is intolerant or has serious adverse reactions.
70% treatment response rate, negative PD-L1 expression can also benefit.
The clinical trial results show that the treatment response rates of the AB groups are 70.
5% and 70.
6%, respectively, reaching the targeted drug treatment response rate.
Figure 2.
The treatment response rate of concurrent radiotherapy and chemotherapy combined with PD-1 in the treatment of stage III lung cancer.
As shown in the figure above, patients in group A and B have achieved very high treatment response rates, and can be obtained regardless of whether PD-L1 expression is negative or positive.
Benefit, that is to say, with such a treatment plan, there is no need to do additional PD-L1 expression detection.
· Patients in group A: The response rate for treatment with PD-L1 expression <1% was 66.
7%, and the response rate for treatment with PD-L1 expression ≥ 1% was 75.
8%.
· Group B patients: The response rate to treatment with PD-L1 expression <1% was 71.
4%, and the response rate to treatment with PD-L1 expression ≥ 1% was 72.
5%.
The treatment response rate of squamous cell carcinoma in group A was 71.
2%, and the treatment response rate of non-squamous cell carcinoma was 69.
2%, which means that the treatment response rates of different subtypes of lung cancer are very similar.
Adverse reactions: 9 patients in group A developed pneumonia of grade 3 or higher, with a probability of 8%.
Seven patients in group B developed pneumonia of grade 3 or higher.
The probability of any adverse reaction above grade 3-5 in group A and group B was 64.
3% and 50%, respectively.
The overall security is controllable.
Implications This clinical trial enrolled patients with locally advanced (stage III) lung cancer, but its findings have implications for many patients with advanced lung cancer or other solid tumors.
At present, the response rate of PD-1 inhibitors in single-agent treatment of lung cancer is only about 20%.
Combining chemotherapy and radiotherapy to assist immunotherapy can improve the efficiency of treatment, but combined treatment will increase the probability of adverse reactions.
So, which drugs are combined? What dose is it administered? How long is the period of use for each drug? These problems need to be verified in clinical trials, and only treatments with controllable risks and superior curative effects will eventually be used in the clinic.
From the data of the KEYNOTE-799 trial, we can see that by optimizing the course of radiotherapy and appropriately reducing the dose of chemotherapeutic drugs by performing radiotherapy and chemotherapy while using drug K, the treatment efficiency can be improved, and the adverse reactions can be controlled.
Looking forward to more clinical trials in the future to bring us more and better treatment options.
Download the Cancer Degree APP to learn more about immunotherapy.
Reference: https://meetinglibrary.
asco.
org/record/196541/abstract Click below to learn more about clinical trial projects.
Children are the flowers of the motherland.
On Children’s Day, a festival that symbolizes hope, cancer degrees will work with you.
Overcome the disease.
Participate in the following interactions to learn more about the functions of the APP.
If it is helpful, you are welcome to download and use the Cancer App.
Click me, click me, click me, click me, click me, click me, review past issues, slide to read more past issues
